Bactiguard Holding AB (publ) (BACTI-B.ST)
SEK 37.2
(-2.11%)
SEK 37.2
(-2.11%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 233.09 Million SEK | -2.35% |
| 2022 | 238.69 Million SEK | -3.73% |
| 2021 | 247.96 Million SEK | -6.08% |
| 2020 | 264.02 Million SEK | 27.01% |
| 2019 | 207.88 Million SEK | 33.14% |
| 2018 | 156.14 Million SEK | -3.9% |
| 2017 | 162.47 Million SEK | 8.32% |
| 2016 | 150 Million SEK | 5.53% |
| 2015 | 142.14 Million SEK | -27.32% |
| 2014 | 195.56 Million SEK | -59.67% |
| 2013 | 484.96 Million SEK | 3.9% |
| 2012 | 466.74 Million SEK | 6.46% |
| 2011 | 438.4 Million SEK | 92.45% |
| 2010 | 227.8 Million SEK | -21.05% |
| 2009 | 288.54 Million SEK | -19.83% |
| 2008 | 359.92 Million SEK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 241.52 Million SEK | 3.62% |
| 2024 Q3 | 174.85 Million SEK | -1.64% |
| 2024 Q2 | 239.29 Million SEK | -0.92% |
| 2023 Q3 | 235.94 Million SEK | -1.33% |
| 2023 FY | 233.09 Million SEK | -2.35% |
| 2023 Q1 | 242 Million SEK | 1.38% |
| 2023 Q2 | 239.12 Million SEK | -1.19% |
| 2023 Q4 | 233.09 Million SEK | -1.21% |
| 2022 Q3 | 241.76 Million SEK | -0.75% |
| 2022 FY | 238.69 Million SEK | -3.73% |
| 2022 Q1 | 245.16 Million SEK | -1.13% |
| 2022 Q4 | 238.69 Million SEK | -1.27% |
| 2022 Q2 | 243.59 Million SEK | -0.64% |
| 2021 Q2 | 265 Million SEK | -0.99% |
| 2021 Q3 | 248.72 Million SEK | -6.14% |
| 2021 Q4 | 247.96 Million SEK | -0.31% |
| 2021 FY | 247.96 Million SEK | -6.08% |
| 2021 Q1 | 267.65 Million SEK | 1.37% |
| 2020 Q2 | 257.89 Million SEK | -1.28% |
| 2020 Q1 | 261.24 Million SEK | 25.67% |
| 2020 Q3 | 269.54 Million SEK | 4.52% |
| 2020 Q4 | 264.02 Million SEK | -2.05% |
| 2020 FY | 264.02 Million SEK | 27.01% |
| 2019 Q2 | 240.77 Million SEK | -0.41% |
| 2019 Q1 | 241.77 Million SEK | 54.84% |
| 2019 Q3 | 223.81 Million SEK | -7.04% |
| 2019 Q4 | 207.88 Million SEK | -7.12% |
| 2019 FY | 207.88 Million SEK | 33.14% |
| 2018 Q3 | 158.83 Million SEK | -1.01% |
| 2018 Q2 | 160.45 Million SEK | -5.9% |
| 2018 Q1 | 170.51 Million SEK | 4.95% |
| 2018 FY | 156.14 Million SEK | -3.9% |
| 2018 Q4 | 156.14 Million SEK | -1.69% |
| 2017 Q4 | 162.47 Million SEK | -0.23% |
| 2017 Q2 | 163.9 Million SEK | -0.01% |
| 2017 Q1 | 163.92 Million SEK | 9.28% |
| 2017 FY | 162.47 Million SEK | 8.32% |
| 2017 Q3 | 162.84 Million SEK | -0.65% |
| 2016 FY | 150 Million SEK | 5.53% |
| 2016 Q4 | 150 Million SEK | 7.62% |
| 2016 Q3 | 139.38 Million SEK | -0.98% |
| 2016 Q2 | 140.76 Million SEK | -0.49% |
| 2016 Q1 | 141.45 Million SEK | -0.49% |
| 2015 FY | 142.14 Million SEK | -27.32% |
| 2015 Q4 | 142.14 Million SEK | 1.25% |
| 2015 Q3 | 140.39 Million SEK | -18.61% |
| 2015 Q2 | 172.49 Million SEK | -6.0% |
| 2015 Q1 | 183.5 Million SEK | -6.17% |
| 2014 Q1 | 493.77 Million SEK | 1.82% |
| 2014 FY | 195.56 Million SEK | -59.67% |
| 2014 Q4 | 195.56 Million SEK | -9.59% |
| 2014 Q3 | 216.31 Million SEK | -16.01% |
| 2014 Q2 | 257.54 Million SEK | -47.84% |
| 2013 Q3 | 453.25 Million SEK | -2.4% |
| 2013 Q4 | 484.96 Million SEK | 7.0% |
| 2013 FY | 484.96 Million SEK | 3.9% |
| 2013 Q1 | 460.7 Million SEK | -1.29% |
| 2013 Q2 | 464.37 Million SEK | 0.8% |
| 2012 Q3 | - SEK | -100.0% |
| 2012 Q2 | 459.94 Million SEK | 0.0% |
| 2012 FY | 466.74 Million SEK | 6.46% |
| 2012 Q4 | 466.74 Million SEK | 0.0% |
| 2011 Q4 | 438.4 Million SEK | 0.0% |
| 2011 FY | 438.4 Million SEK | 92.45% |
| 2010 FY | 227.8 Million SEK | -21.05% |
| 2009 FY | 288.54 Million SEK | -19.83% |
| 2008 FY | 359.92 Million SEK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Acarix AB (publ) | - SEK | -Infinity% |
| ADDvise Group AB (publ) | 1.61 Billion SEK | 85.552% |
| ADDvise Group AB (publ) | 1.61 Billion SEK | 85.552% |
| Arcoma AB | 3.87 Million SEK | -5918.564% |
| BICO Group AB (publ) | 1.85 Billion SEK | 87.421% |
| Boule Diagnostics AB (publ) | 166.1 Million SEK | -40.337% |
| CellaVision AB (publ) | 64.7 Million SEK | -260.26% |
| Clinical Laserthermia Systems AB (publ) | 454 Thousand SEK | -51243.392% |
| Chordate Medical Holding AB (publ) | - SEK | -Infinity% |
| C-Rad AB (publ) | 1.8 Million SEK | -12849.944% |
| Duearity AB (publ) | 10.58 Million SEK | -2102.788% |
| Dignitana AB (publ) | 19.1 Million SEK | -1120.158% |
| Episurf Medical AB (publ) | 5.2 Million SEK | -4382.673% |
| Getinge AB (publ) | 8.07 Billion SEK | 97.114% |
| Scandinavian Real Heart AB (Publ) | 8.24 Million SEK | -2725.571% |
| Iconovo AB (publ) | 7.72 Million SEK | -2917.498% |
| Integrum AB (publ) | 6.42 Million SEK | -3528.463% |
| Luxbright AB (publ) | 206.02 Thousand SEK | -113041.673% |
| Mentice AB (publ) | 9.55 Million SEK | -2339.039% |
| OssDsign AB (publ) | 3.15 Million SEK | -7299.968% |
| Paxman AB (publ) | 13.57 Million SEK | -1617.752% |
| Promimic AB (publ) | - SEK | -Infinity% |
| Qlife Holding AB (publ) | 20.73 Million SEK | -1024.398% |
| SciBase Holding AB (publ) | 6.79 Million SEK | -3329.439% |
| ScandiDos AB (publ) | - SEK | -Infinity% |
| Sectra AB (publ) | 31.78 Million SEK | -633.292% |
| Sedana Medical AB (publ) | 4.3 Million SEK | -5313.353% |
| Senzime AB (publ) | 11.46 Million SEK | -1932.604% |
| SpectraCure AB (publ) | 6.71 Million SEK | -3370.284% |
| Stille AB | 62.94 Million SEK | -270.339% |
| Vitrolife AB (publ) | 2.08 Billion SEK | 88.842% |
| Xvivo Perfusion AB (publ) | 31.43 Million SEK | -641.48% |